首页> 外文期刊>World journal of gastroenterology : >Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma.
【24h】

Portal vein thrombosis and arterioportal shunts: Effects on tumor response after chemoembolization of hepatocellular carcinoma.

机译:门静脉血栓形成和动静脉分流:对肝细胞癌化学栓塞后对肿瘤反应的影响。

获取原文
获取原文并翻译 | 示例
           

摘要

AIM: To evaluate the effect of portal vein thrombosis and arterioportal shunts on local tumor response in advanced cases of unresectable hepatocellular carcinoma treated by transarterial chemoembolization. METHODS: A retrospective study included 39 patients (mean age: 66.4 years, range: 45-79 years, SD: 7) with unresectable hepatocellular carcinoma (HCC) who were treated with repetitive transarterial chemoembolization (TACE) in the period between March 2006 and October 2009. The effect of portal vein thrombosis (PVT) (in 19 out of 39 patients), the presence of arterioportal shunt (APS) (in 7 out of 39), the underlying liver pathology, Child-Pugh score, initial tumor volume, number of tumors and tumor margin definition on imaging were correlated with the local tumor response after TACE. The initial and end therapy local tumor responses were evaluated according to the response evaluation criteria in solid tumors (RECIST) and magnetic resonance imaging volumetric measurements. RESULTS: The treatment protocols were well tolerated by all patients with no major complications. Local tumor response for all patients according to RECIST criteria were partial response in one patient (2.6%), stable disease in 34 patients (87.1%), and progressive disease in 4 patients (10.2%). The MR volumetric measurements showed that the PVT, APS, underlying liver pathology and tumor margin definition were statistically significant prognostic factors for the local tumor response (P = 0.018, P = 0.008, P = 0.034 and P = 0.001, respectively). The overall 6-, 12- and 18-mo survival rates from the initial TACE were 79.5%, 37.5% and 21%, respectively. CONCLUSION: TACE may be exploited safely for palliative tumor control in patients with advanced unresectable HCC; however, tumor response is significantly affected by the presence or absence of PVT and APS.
机译:目的:评估经动脉化疗栓塞治疗的晚期不可切除肝细胞癌晚期患者中门静脉血栓形成和动门分流对局部肿瘤反应的影响。方法:一项回顾性研究纳入了2006年3月至2006年3月期间接受经皮穿刺反复栓塞术(TACE)治疗的39例平均手术年龄为66.4岁,范围为45-79岁,SD为7的不可切除肝细胞癌(HCC)的患者。 2009年10月。门静脉血栓形成(PVT)(39例中的19例),存在动静脉分流(APS)(39例中的7例),基础肝病理学,Child-Pugh评分,初始肿瘤体积的影响,肿瘤数目和影像学上的肿瘤边缘定义与TACE术后局部肿瘤反应相关。根据实体瘤中的反应评估标准(RECIST)和磁共振成像体积测量,评估初始和结束治疗后局部肿瘤的反应。结果:所有无严重并发症的患者对治疗方案的耐受性良好。根据RECIST标准,所有患者的局部肿瘤反应为1例(2.6%)部分缓解,34例(87.1%)稳定疾病和4例(10.2%)进展性疾病。 MR容积测量显示,PVT,APS,潜在的肝脏病理学和肿瘤切缘定义是局部肿瘤反应的统计学显着预后因素(分别为P = 0.018,P = 0.008,P = 0.034和P = 0.001)。从最初的TACE总体来看,6个月,12个月和18个月生存率分别为79.5%,37.5%和21%。结论:TACE可以安全地用于晚期不能切除的HCC患者的姑息性肿瘤控制。但是,是否存在PVT和APS会显着影响肿瘤反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号